BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 10732774)

  • 1. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
    van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL
    Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.
    de Wilt JH; Soma G; ten Hagen TL; Kanou J; Takagi K; Nooijen PT; Seynhaevel AL; Eggermont AM
    Anticancer Res; 2000; 20(5B):3491-6. PubMed ID: 11131652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
    van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM
    Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
    Brunstein F; Hoving S; Seynhaeve AL; van Tiel ST; Guetens G; de Bruijn EA; Eggermont AM; ten Hagen TL
    J Natl Cancer Inst; 2004 Nov; 96(21):1603-10. PubMed ID: 15523089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.
    de Wilt JH; Manusama ER; van Etten B; van Tiel ST; Jorna AS; Seynhaeve AL; ten Hagen TL; Eggermont AM
    Br J Cancer; 2000 Nov; 83(9):1176-82. PubMed ID: 11027431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
    Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.
    Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
    Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
    Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.
    Lejeune FJ; Rüegg C
    Bull Cancer; 2006 Aug; 93(8):E90-100. PubMed ID: 16935777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
    Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
    Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
    de Wilt JH; ten Hagen TL; de Boeck G; van Tiel ST; de Bruijn EA; Eggermont AM
    Br J Cancer; 2000 Mar; 82(5):1000-3. PubMed ID: 10737379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.
    Pencavel TD; Wilkinson MJ; Mansfield DC; Khan AA; Seth R; Karapanagiotou EM; Roulstone V; Aguilar RJ; Chen NG; Szalay AA; Hayes AJ; Harrington KJ
    Int J Cancer; 2015 Feb; 136(4):965-76. PubMed ID: 24978211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study.
    Gutman M; Sofer D; Lev-Chelouche D; Merimsky O; Klausner JM
    Invasion Metastasis; 1997; 17(4):169-75. PubMed ID: 9778589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
    Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
    Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity.
    Bickels J; Manusama ER; Gutman M; Eggermont AM; Kollender Y; Abu-Abid S; Van Geel AN; Lev-Shlush D; Klausner JM; Meller I
    Eur J Surg Oncol; 1999 Oct; 25(5):509-14. PubMed ID: 10527599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application.
    van Der Veen AH; ten Hagen TL; de Wilt JH; van Ijken MG; Eggermont AM
    Anticancer Res; 2000; 20(5B):3467-74. PubMed ID: 11131649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
    Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
    J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma.
    Nachmany I; Subhi A; Meller I; Gutman M; Lahat G; Merimsky O; Klausner JM
    Eur J Surg Oncol; 2009 Feb; 35(2):209-14. PubMed ID: 18295442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.
    Rossi CR; Mocellin S; Pilati P; Foletto M; Campana L; Quintieri L; De Salvo GL; Lise M
    Ann Surg Oncol; 2005 May; 12(5):398-405. PubMed ID: 15915374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.